Potential risks and benefits of HIV treatment simplification: A simulation model of a proposed clinical trial

Clinical Infectious Diseases

Volumn 45, Issue 8, 2007, Pages 1062-1070

  Schackman, Bruce R ^a   Scott, Callie A ^b   Sax, Paul E ^c,e   Losina, Elena ^b,c,f   Wilkin, Timothy J ^a   McKinnon, John E ^g   Swindells, Susan ^h   Weinstein, Milton C ^d   Freedberg, Kenneth A ^b,c,d,f  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^g UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ATAZANAVIR; DARUNAVIR; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; RITONAVIR; STAVUDINE; TENOFOVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PROTEINASE INHIBITOR;

ADULT; ANEMIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY; LIFE EXPECTANCY; LIPOATROPHY; MALE; MULTICENTER STUDY; NEPHROTOXICITY; NEUROPATHY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; SIMULATION; BIOLOGICAL MODEL; COMPARATIVE STUDY; COMPUTER SIMULATION; DRUG COMBINATION; DRUG COST; ECONOMICS; MIDDLE AGED; RISK ASSESSMENT; TREATMENT OUTCOME;

ADULT; ANTI-HIV AGENTS; COMPUTER SIMULATION; DRUG COSTS; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; LIFE EXPECTANCY; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; QUALITY-ADJUSTED LIFE YEARS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 34848824668     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/521933     Document Type: Article

References (47)

1. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents - a working group of the Office of AIDS Research Advisory Council. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 10 October 2006. Available at: http://aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf. Accessed 19 January 2007.
2. Arribas J, Pulido F, Delgado R, et al. Lopinavir/ritonavir as single-drug maintenance therapy in patients with HIV-1 viral suppression: forty eight week results of a randomized, controlled, open label, clinical trial (OK04 Study) [abstract WEPE12.3C05]. In: Program and abstracts of the XVI International AIDS Conference (Toronto, Canada). Geneva: International AIDS Society, 2006.
3. Arribas JR, Pulido F, Delgado R, et al. Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study). J Acquir Immune Defic Syndr 2005; 40:280-7.
4. Cameron D, da Silva B, Arribas J, et al. A two-year randomized controlled clinical trial in antiretroviral-naive subjects using lopinavir/ritonavir (LPV/r) monotherapy after initial induction treatment compared to an efavirenz (EFV) 3-drug regimen (Study M03-613) [abstract THLB0201]. In: Program and abstracts of the XVI International AIDS Conference (Toronto, Canada). Geneva: International AIDS Society, 2006.
5. Delfraissy JF, Flandre P, Delaugerre C, et al. MONARK trial (MONotherapy AntiRetroviral Kaletra): 48-week analysis of lopinavir/ritonavir (LPV/r) monotherapy compared to LPV/r + zidovudine/lamivudine (AZT/3TC) in antiretroviral-naive patients [abstract THLB0202]. In: Program and abstracts of the XVI International AIDS Conference (Toronto, Canada). Geneva: International AIDS Society, 2006.
6. Gathe JC, Washington M, Piot D, Mayberry C. Preliminary pilot data on the safety and efficacy of Kaletra (LPV/r) dosed alone for the treatment of HIV in ARV-naive patients: greater than or equal 24 data [abstract H-845]. In: Program and abstracts of the 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago, IL). Washington, DC: American Society for Microbiology, 2003.
7. Kahlert C, Hupfer M, Wagels T, et al. Ritonavir boosted indinavir treatment as a simplified maintenance "mono"-therapy for HIV infection. AIDS 2004; 18:955-7.
8. Nunes EP, Oliveira MS, Almeida MMTB, et al. 48-Week efficacy and safety results of simplification to single agent lopinavir/ritonavir (LPV/r) regimen in patients suppressed below 80 copies/mL on HAART- the KalMo study [abstract TUAB0103]. In: Program and abstracts of the XVI International AIDS Conference (Toronto, Canada). Geneva: International AIDS Society, 2006.
9. Pierone G Jr, Mieras J, Bulgin-Coleman D, et al. A pilot study of switch to lopinavir/ritonavir (LPV/r) monotherapy from nonnucleoside reverse transcriptase inhibitor-based therapy. HIV Clin Trials 2006; 7:237-45.
10. Swindells S, DiRienzo AG, Wilkin T, et al. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression. JAMA 2006; 296:806-14.
11. Vernazza P, Daneel S, Schiffer V, et al. Simplified protease-inhibitor- only regimen with ritonavir-boosted atazanavir (ATARITMO-study) [abstract WEPE0073]. In: Program and abstracts of the XVI International AIDS Conference (Toronto, Canada). Geneva: International AIDS Society, 2006.
12. Karlstrom O, Josephson F, Sonnerborg A. Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy. J Acquir Immune Defic Syndr 2007; 44:417-22.
13. Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med 2001; 344:824-31.
14. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost effectiveness in health and medicine. New York: Oxford University Press, 1996.
15. Schackman BR, Gebo KA, Walensky RP, et al. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care 2006; 44:990-7.
16. Samet JH, Freedberg KA, Savetsky JB, Sullivan LM, Stein MD. Understanding delay to medical care for HIV infection: the long-term non-presenter. AIDS 2001; 15:77-85.
17. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292:191-201.
18. Clotet B, Raffi F, Cooper D, et al. Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendations. AIDS 2004; 18:1137-46.
19. Johnson M, Grinsztejn B, Rodriguez C, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 2005; 19:685-94.
20. Albrecht MA, Bosch RJ, Hammer SM, et al. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. N Engl J Med 2001; 345:398-407.
21. Katlama C, Berger D, Bellos N, et al. Efficacy of TMC114/r in 3-class experienced patients with limited treatment options: 24-week planned interim analysis of 2 96-week multinational dose-finding trials [abstract 164LB]. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections (Boston, MA). Alexandria, VA: Foundation for Retrovirology and Human Health, 2005.
22. Losina E, Islam R, Pollock AC, Sax PE, Freedberg KA, Walensky RP. Effectiveness of antiretroviral therapy after protease inhibitor failure: an analytic overview. Clin Infect Dis 2004; 38:1613-22.
23. Landay A, da Silva BA, King MS, et al. Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir-ritonavir treatment. Clin Infect Dis 2007; 44:749-54.
24. Hackett JR Jr, Holzmayer V, Marlowe N, et al. Selection of protease inhibitor (PI) resistance mutations during virological failure of lopinavir/ritonavir (LPV/r) monotherapy in an induction-maintenance study [abstract 75]. Antivir Ther 2006; 11:S85.
25. Norton M, Delaugere C, Batot G, Delfraissy JF, Rouzioux C. Drug resistance outcomes in a trial comparing lopinavir/ritonavir (LPV/r) monotherapy to LPV/r + zidovudine/lamivudine (MONARK Trial) [abstract 74]. Antivir Ther 2006; 11:S84.
26. Bagust A, Beale S. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ 2005; 14:217-30.
27. Claessens YE, Chiche JD, Mira JP, Cariou A. Bench-to-bedside review: severe lactic acidosis in HIV patients treated with nucleoside analogue reverse transcriptase inhibitors. Crit Care 2003; 7:226-32.
28. Guo JJ, Jang R, Louder A, Cluxton RJ. Acute pancreatitis associated with different combination therapies in patients infected with human immunodeficiency virus. Pharmacotherapy 2005; 25:1044-54.
29. Lenert LA, Feddersen M, Sturley A, Lee D. Adverse effects of medications and trade-offs between length of life and quality of life in human immunodeficiency virus infection. Am J Med 2002; 113:229-32.
30. Moore RD, Keruly JC, Chaisson RE. Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugs. AIDS 2001; 15:617-20.
31. Moore RD, Wong WM, Keruly JC, McArthur JC. Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hydroxyurea. AIDS 2000; 14:273-8.
32. Nelson M, Cooper D, Schooley R, et al. The safety of tenofovir DF for the treatment of HIV infection: the first 4 years [poster 781]. In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections (Denver, CO): Alexandria, VA: Foundation for Retrovirology and Human Health, 2006.
33. Nolan D, Mallal S. Complications associated with NRTI therapy: update on clinical features and possible pathogenic mechanisms. Antivir Ther 2004; 9:849-63.
34. Robbins GK, De Gruttola V, Shafer RW, et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003; 349:2293-303.
35. Schackman BR, Freedberg KA, Weinstein MC, et al. Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults. Arch Intern Med 2002; 162:2478-86.
36. Steigbigel R, Kumar P, Eron J, et al. Results of BENCHMRK-2, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistance virus [abstract 105bLB]. In: Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections (Los Angeles, CA): Alexandria, VA: Foundation for Retrovirology and Human Health, 2007.
37. Study comparing efficacy and safety of darunavir boosted with ritonavir to HART with 2 NRTI and darunavir boosted with ritonavir in HIV-1 infected patients. Available at: http://clinicaltrials.gov/show/NCT00421551. Accessed 14 February 2007.
38. Colonno R, Rose R, McLaren C, Thiry A, Parkin N, Friborg J. Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens. J Infect Dis 2004; 189:1802-10.
39. Paltiel AD, Goldie SJ, Losina E, et al. Preevaluation of clinical trial data: the case of preemptive cytomegalovirus therapy in patients with human immunodeficiency virus. Clin Infect Dis 2001; 32:783-93.
40. Multicenter AIDS Cohort Study (MACS) public dataset: release PO4. Springfield, VA: National Technical Information Service, 1995.
41. Cole SR, Hernan MA, Robins JM, et al. Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. Am J Epidemiol 2003; 158:687-94.
42. Masur H, Kaplan JE, Holmes KK. Guidelines for preventing opportunistic infections among HIV-infected persons - 2002: recommendations of the US Public Health Service and the Infectious Diseases Society of America. Ann Intern Med 2002; 137:435-78.
43. Red Book. Montvale, NJ: Thomson PDR, 2005.
44. Schackman BR, Goldie SJ, Freedberg KA, Losina E, Brazier J, Weinstein MC. Comparison of health state utilities using community and patient preference weights derived from a survey of patients with HIV/AIDS. Med Decis Making 2002; 22:27-38.
45. Paltiel AD, Scharfstein JA, Seage GR 3rd, et al. A Monte Carlo simulation of advanced HIV disease: application to prevention of CMV infection. Med Decis Making 1998; 18:S93-105.
46. Paltiel AD, Weinstein MC, Kimmel AD, et al. Expanded screening for HIV in the United States - an analysis of cost-effectiveness. N Engl J Med 2005; 352:586-95.
47. Walensky RP, Paltiel AD, Losina E, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis 2006; 194:11-9.